JP2022524434A5 - - Google Patents
Info
- Publication number
- JP2022524434A5 JP2022524434A5 JP2021554696A JP2021554696A JP2022524434A5 JP 2022524434 A5 JP2022524434 A5 JP 2022524434A5 JP 2021554696 A JP2021554696 A JP 2021554696A JP 2021554696 A JP2021554696 A JP 2021554696A JP 2022524434 A5 JP2022524434 A5 JP 2022524434A5
- Authority
- JP
- Japan
- Prior art keywords
- cedna vector
- itrs
- prior
- adjacent
- vector according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025016352A JP2025073123A (ja) | 2019-03-13 | 2025-02-03 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025172911A JP2026002894A (ja) | 2019-03-13 | 2025-10-14 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817904P | 2019-03-13 | 2019-03-13 | |
| US62/817,904 | 2019-03-13 | ||
| US201962856432P | 2019-06-03 | 2019-06-03 | |
| US62/856,432 | 2019-06-03 | ||
| PCT/US2020/022738 WO2020186207A2 (en) | 2019-03-13 | 2020-03-13 | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025016352A Division JP2025073123A (ja) | 2019-03-13 | 2025-02-03 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025172911A Division JP2026002894A (ja) | 2019-03-13 | 2025-10-14 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524434A JP2022524434A (ja) | 2022-05-02 |
| JP2022524434A5 true JP2022524434A5 (enExample) | 2023-03-22 |
| JP7795357B2 JP7795357B2 (ja) | 2026-01-07 |
Family
ID=72426821
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021554696A Active JP7795357B2 (ja) | 2019-03-13 | 2020-03-13 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025016352A Pending JP2025073123A (ja) | 2019-03-13 | 2025-02-03 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025172911A Withdrawn JP2026002894A (ja) | 2019-03-13 | 2025-10-14 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025016352A Pending JP2025073123A (ja) | 2019-03-13 | 2025-02-03 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025172911A Withdrawn JP2026002894A (ja) | 2019-03-13 | 2025-10-14 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12338275B2 (enExample) |
| EP (1) | EP3938523A4 (enExample) |
| JP (3) | JP7795357B2 (enExample) |
| KR (1) | KR20210151785A (enExample) |
| CN (1) | CN113874513A (enExample) |
| AU (1) | AU2020234713A1 (enExample) |
| BR (1) | BR112021017853A2 (enExample) |
| CA (1) | CA3133255A1 (enExample) |
| IL (1) | IL286284A (enExample) |
| MA (1) | MA55313A (enExample) |
| MX (1) | MX2021011039A (enExample) |
| SG (1) | SG11202109850SA (enExample) |
| WO (1) | WO2020186207A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| JP2023535632A (ja) | 2020-07-27 | 2023-08-18 | アンジャリウム バイオサイエンシズ エージー | Ｄｎａ分子の組成物、その作製方法、及びその使用方法 |
| US20220356490A1 (en) * | 2020-08-23 | 2022-11-10 | Bioverativ Therapeutics Inc. | Baculovirus expression system |
| WO2023069948A1 (en) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| EP4428237A4 (en) * | 2021-11-02 | 2026-02-25 | Gritgen Therapeutics Ltd | ISOLATED NUCLEIC ACID MOLECULE AND ITS USES |
| JP2023089774A (ja) * | 2021-12-16 | 2023-06-28 | 株式会社三洋物産 | 遊技機 |
| JP2025504404A (ja) * | 2022-01-14 | 2025-02-12 | アンジャリウム バイオサイエンシズ エージー | Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法 |
| WO2025110984A1 (en) * | 2023-11-21 | 2025-05-30 | Hydrogene Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
| KR20260011950A (ko) | 2024-07-17 | 2026-01-26 | 이민형 | 수질 시료 채취 드론 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100323957A1 (en) * | 2007-11-19 | 2010-12-23 | The Regents Of The University Of California The Office Of The President | Novel assay for inhibitors of egfr |
| NZ596058A (en) * | 2009-04-30 | 2013-08-30 | Cytos Biotechnology Ag | Influenza hemagglutinin compositions and uses thereof |
| EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| WO2013093760A2 (en) * | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| WO2013151665A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| WO2014127215A1 (en) | 2013-02-15 | 2014-08-21 | Biogen Idec Ma Inc. | Optimized factor viii gene |
| EP3044231B1 (en) * | 2013-09-12 | 2020-08-05 | BioMarin Pharmaceutical Inc. | Aav vectors comprising a gene encoding factor viii |
| GB2526339A (en) * | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
| US20190032079A1 (en) * | 2015-08-03 | 2019-01-31 | Myodopa Limited | Systemic synthesis and regulation of l-dopa |
| TW202446416A (zh) | 2015-09-24 | 2024-12-01 | 美商拜奧馬林製藥公司 | 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物 |
| MY189674A (en) | 2015-10-28 | 2022-02-24 | Sangamo Therapeutics Inc | Liver-specific constructs, factor viii expression cassettes and methods of use thereof |
| PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| MX2018010633A (es) * | 2016-03-03 | 2019-06-13 | Univ Massachusetts | Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral. |
| MX2018012537A (es) | 2016-04-15 | 2019-02-25 | Univ Pennsylvania | Terapia de genes para tratar hemofilia a. |
| JP7235511B2 (ja) * | 2016-06-24 | 2023-03-08 | モガム・インスティテュート・フォー・バイオメディカル・リサーチ | 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート |
| PE20200722A1 (es) | 2017-08-01 | 2020-07-21 | Spark Therapeutics Inc | Metodos de terapia genica del factor viii (fviii) |
| NZ762100A (en) * | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
-
2020
- 2020-03-13 SG SG11202109850S patent/SG11202109850SA/en unknown
- 2020-03-13 CN CN202080036209.7A patent/CN113874513A/zh active Pending
- 2020-03-13 US US17/437,123 patent/US12338275B2/en active Active
- 2020-03-13 EP EP20769344.1A patent/EP3938523A4/en active Pending
- 2020-03-13 AU AU2020234713A patent/AU2020234713A1/en active Pending
- 2020-03-13 MA MA055313A patent/MA55313A/fr unknown
- 2020-03-13 MX MX2021011039A patent/MX2021011039A/es unknown
- 2020-03-13 CA CA3133255A patent/CA3133255A1/en active Pending
- 2020-03-13 BR BR112021017853A patent/BR112021017853A2/pt unknown
- 2020-03-13 WO PCT/US2020/022738 patent/WO2020186207A2/en not_active Ceased
- 2020-03-13 JP JP2021554696A patent/JP7795357B2/ja active Active
- 2020-03-13 KR KR1020217029545A patent/KR20210151785A/ko active Pending
-
2021
- 2021-09-12 IL IL286284A patent/IL286284A/en unknown
-
2025
- 2025-02-03 JP JP2025016352A patent/JP2025073123A/ja active Pending
- 2025-05-21 US US19/214,171 patent/US20250282848A1/en active Pending
- 2025-10-14 JP JP2025172911A patent/JP2026002894A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022524434A5 (enExample) | ||
| JP2024009857A5 (enExample) | ||
| JP2022549380A5 (enExample) | ||
| JP2022525302A5 (enExample) | ||
| JP2020532981A5 (enExample) | ||
| JP2021087431A5 (enExample) | ||
| JP2021003120A5 (enExample) | ||
| JP2018522529A5 (enExample) | ||
| JP2021513999A5 (enExample) | ||
| JP2023520764A5 (enExample) | ||
| JP2022529631A5 (enExample) | ||
| IL299325B2 (en) | Acid-alpha glucosidase variants and uses thereof | |
| JP2017509632A5 (enExample) | ||
| JP2023520763A5 (enExample) | ||
| JP2020519284A5 (enExample) | ||
| JP2024099770A5 (enExample) | ||
| JP2022551744A5 (enExample) | ||
| JP2020533276A5 (enExample) | ||
| US20240376498A1 (en) | Transgene cassettes, aav vectors and aav viral vectors for the expression of human codon-optimized slc6a1 | |
| JP2021534814A5 (enExample) | ||
| CA3158518A1 (en) | Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases | |
| JP2017529395A5 (enExample) | ||
| JP2023542131A5 (enExample) | ||
| JP2023537358A5 (enExample) | ||
| JP2023059858A5 (enExample) |